Cullinan Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 8731 https://www.cullinanoncology.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Oncology Inc

12 Cheap Healthcare Stocks to Buy in 2023 - Mar 29th, 2023 2:13 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines - Mar 27th, 2023 11:00 am
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting - Mar 14th, 2023 8:35 pm
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 9th, 2023 12:00 pm
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference - Feb 27th, 2023 1:00 pm
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed - Feb 14th, 2023 12:00 am
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference - Feb 2nd, 2023 9:01 pm
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 1st, 2023 9:42 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - Jan 24th, 2023 1:00 pm
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds - Jan 23rd, 2023 4:07 pm
11 Cheap Value Stocks to Buy According to Seth Klarman - Dec 29th, 2022 3:31 am
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Nov 14th, 2022 12:00 pm
Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors - Nov 2nd, 2022 12:00 pm
Cullinan Oncology to Participate in Upcoming Investor Conferences - Nov 1st, 2022 11:00 am
Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 - Oct 25th, 2022 11:00 am
Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference - Sep 7th, 2022 12:00 pm
Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer - Aug 15th, 2022 8:57 pm
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Aug 10th, 2022 11:00 am
Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference - Aug 1st, 2022 12:00 pm
Cullinan Oncology to Participate in William Blair Biotech Focus Conference - Jul 5th, 2022 8:01 pm